TPTX News and Press, Turning Point Therapeutics Inc. From 05/25/21

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its ...

Turning Point Therapeutics (TPTX) announces the appointment of Kumar Srinivasan as the company's executive vice president and chief business officer, effective June 1.Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, and most recently as ...

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president ...

Turning Point Therapeutics, Inc. (TPTX) Q1 2021 Earnings Conference Call May 05, 2021, 05:00 PM ET Company Participants Jim Mazzola - SVP, Communication and IR Athena Countouriotis - President and CEO Mohammad Hirmand - Chief Medical Officer Conference Call Participants Charles Zhu - Guggenhe...

Turning Point Therapeutics (TPTX): Q1 GAAP EPS of -$0.73 misses by $0.12.Revenue of $25.2M beats by $7.7M.Press Release For further details see: Turning Point Therapeutics EPS misses by $0.12, beats on revenue

FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022 Investigational New Drug Application Cleared for Combination of Repo...

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets o...

Turning Point (TPTX) announces the initiation of its Phase 1/2 FORGE-1 study of TPX-0131, a potent inhibitor of the anaplastic lymphoma kinase ((ALK)) and multiple resistant mutations of ALK.The Phase 1 dose finding portion of the FORGE-1 study will enroll patients with locally advanced or me...

Investigational New Drug Application Cleared Study Initiated in Australia, with U.S. Site Activations Now Planned SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation th...

SAN DIEGO, April 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced new preclinical data supporting the ongoing development of three of its dru...